Vor Biopharma (VOR) Total Current Liabilities (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Total Current Liabilities data on file, last reported at $16.1 million in Q1 2026.

• Quarterly Total Current Liabilities fell 3.89% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (down 3.89% YoY) and the FY2025 annual result came in at $25.2 million, up 35.24% from the prior year.
• Total Current Liabilities declined to $16.1 million in Q1 2026 per VOR's latest filing, from $25.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $58.8 million in Q2 2025 and bottomed at $11.1 million in Q3 2022.
• The 5-year median for Total Current Liabilities is $15.4 million (2023), against an average of $18.0 million.
• The widest annual swing landed in 2023, when Total Current Liabilities tumbled 30.68%; it then jumped 325.86% in 2025.
• Tracing VOR's Total Current Liabilities over 5 years: stood at $13.1 million in 2022, then grew by 18.7% to $15.6 million in 2023, then advanced by 19.52% to $18.6 million in 2024, then jumped by 35.24% to $25.2 million in 2025, then plunged by 36.13% to $16.1 million in 2026.
• Per Business Quant, the three latest VOR Total Current Liabilities figures stand at $16.1 million (Q1 2026), $25.2 million (Q4 2025), and $18.8 million (Q3 2025).

Peer Comparison